Table 5

Effect of surveillance endoscopy on stage, treatment, survival and cancer-related mortality in patients with Barrett's oesophagus and newly diagnosed oesophageal adenocarcinoma (EAC), compared with EAC detected by diagnostic endoscopy in symptomatic patients

OR/HR*95% CI
Early stage (n=148/198 surveillance and 36/97 diagnostic)
 Unadjusted5.022.98 to 8.45
 Adjusted† (without treatment)6.033.40 to 10.72
Receipt of any treatment (n=151/209 surveillance and 51/102 diagnostic)
 Unadjusted2.601.59 to 4.26
 Adjusted† (without stage)2.701.60 to 4.56
 Adjusted with stage1.110.56 to 2.18
Overall mortality (n=81/209 surveillance and 73/102 diagnostic)
 Unadjusted0.330.24 to 0.46
 Adjusted† (without stage or treatment)0.280.20 to 0.40
 Adjusted (including stage)0.640.41 to 0.99
 Adjusted (including stage and treatment)0.620.40 to 0.97
Overall mortality corrected for lead time (n=81/209 surveillance and 73/102 diagnostic)
 Unadjusted0.540.39 to 0.74
 Adjusted† (without stage or treatment)0.530.37 to 0.76
 Adjusted (including stage and treatment)1.290.81 to 2.06
EAC-related mortality (n=71/209 surveillance and 67/102 diagnostic)
 Unadjusted0.320.23 to 0.45
 Adjusted† (without stage or treatment)0.280.20 to 0.41
 Adjusted (including stage and treatment)0.630.39 to 1.00
EAC-related mortality corrected for lead time (71/209 surveillance and 67/102 diagnostic)
 Unadjusted0.510.37 to 0.71
 Adjusted† (without stage or treatment)0.520.36 to 0.75
 Adjusted (including stage and treatment)1.270.78 to 2.07
  • *HRs were used for all mortality-related outcomes. ORs were used for remaining outcomes.

  • †Adjusted for year of EAC diagnosis, age, race, propensity of EGD, comorbidity score, total number of VA visit and GI clinic visit.

  • EGD, oesophagogastroduodenoscopy; VA, Veteran Affairs.